Literature DB >> 26937021

Identification of Tazarotenic Acid as the First Xenobiotic Substrate of Human Retinoic Acid Hydroxylase CYP26A1 and CYP26B1.

Robert S Foti1, Nina Isoherranen2, Alex Zelter2, Leslie J Dickmann2, Brian R Buttrick2, Philippe Diaz2, Dominique Douguet2.   

Abstract

Cytochrome P450 (CYP) 26A1 and 26B1 are heme-containing enzymes responsible for metabolizing all-trans retinoic acid (at-RA). No crystal structures have been solved, and therefore homology models that provide structural information are extremely valuable for the development of inhibitors of cytochrome P450 family 26 (CYP26). The objectives of this study were to use homology models of CYP26A1 and CYP26B1 to characterize substrate binding characteristics, to compare structural aspects of their active sites, and to support the role of CYP26 in the metabolism of xenobiotics. Each model was verified by dockingat-RA in the active site and comparing the results to known metabolic profiles ofat-RA. The models were then used to predict the metabolic sites of tazarotenic acid with results verified by in vitro metabolite identification experiments. The CYP26A1 and CYP26B1 homology models predicted that the benzothiopyranyl moiety of tazarotenic acid would be oriented toward the heme of each enzyme and suggested that tazarotenic acid would be a substrate of CYP26A1 and CYP26B1. Metabolite identification experiments indicated that CYP26A1 and CYP26B1 oxidatively metabolized tazarotenic acid on the predicted moiety, with in vitro rates of metabolite formation by CYP26A1 and CYP26B1 being the highest across a panel of enzymes. Molecular analysis of the active sites estimated the active-site volumes of CYP26A1 and CYP26B1 to be 918 Å(3)and 977 Å(3), respectively. Overall, the homology models presented herein describe the enzyme characteristics leading to the metabolism of tazarotenic acid by CYP26A1 and CYP26B1 and support a potential role for the CYP26 enzymes in the metabolism of xenobiotics.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26937021      PMCID: PMC4851321          DOI: 10.1124/jpet.116.232637

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  53 in total

1.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy.

Authors:  Richard A Friesner; Jay L Banks; Robert B Murphy; Thomas A Halgren; Jasna J Klicic; Daniel T Mainz; Matthew P Repasky; Eric H Knoll; Mee Shelley; Jason K Perry; David E Shaw; Perry Francis; Peter S Shenkin
Journal:  J Med Chem       Date:  2004-03-25       Impact factor: 7.446

2.  Impact of incubation conditions on bufuralol human clearance predictions: enzyme lability and nonspecific binding.

Authors:  Robert S Foti; Michael B Fisher
Journal:  Drug Metab Dispos       Date:  2004-03       Impact factor: 3.922

3.  Small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26): synthesis and biological evaluation of imidazole methyl 3-(4-(aryl-2-ylamino)phenyl)propanoates.

Authors:  Mohamed S Gomaa; Caroline E Bridgens; Ahmed S Aboraia; Gareth J Veal; Christopher P F Redfern; Andrea Brancale; Jane L Armstrong; Claire Simons
Journal:  J Med Chem       Date:  2011-03-23       Impact factor: 7.446

4.  Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes.

Authors:  Richard A Friesner; Robert B Murphy; Matthew P Repasky; Leah L Frye; Jeremy R Greenwood; Thomas A Halgren; Paul C Sanschagrin; Daniel T Mainz
Journal:  J Med Chem       Date:  2006-10-19       Impact factor: 7.446

5.  Identification of the human cytochrome P450, P450RAI-2, which is predominantly expressed in the adult cerebellum and is responsible for all-trans-retinoic acid metabolism.

Authors:  J A White; H Ramshaw; M Taimi; W Stangle; A Zhang; S Everingham; S Creighton; S P Tam; G Jones; M Petkovich
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

Review 6.  Efficacy and safety of topical tazarotene: a review.

Authors:  Rakhashandra Talpur; Katherine Cox; Madeleine Duvic
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-02       Impact factor: 4.481

Review 7.  Cytochrome p450 retinoic acid 4-hydroxylase inhibitors: potential agents for cancer therapy.

Authors:  V C O Njar
Journal:  Mini Rev Med Chem       Date:  2002-06       Impact factor: 3.862

Review 8.  Cytochrome P450s in the regulation of cellular retinoic acid metabolism.

Authors:  A Catharine Ross; Reza Zolfaghari
Journal:  Annu Rev Nutr       Date:  2011-08-21       Impact factor: 11.848

9.  Expression and functional characterization of cytochrome P450 26A1, a retinoic acid hydroxylase.

Authors:  Justin D Lutz; Vaishali Dixit; Catherine K Yeung; Leslie J Dickmann; Alex Zelter; Jayne E Thatcher; Wendel L Nelson; Nina Isoherranen
Journal:  Biochem Pharmacol       Date:  2008-10-17       Impact factor: 5.858

10.  Homology models of human all-trans retinoic acid metabolizing enzymes CYP26B1 and CYP26B1 spliced variant.

Authors:  Patricia Saenz-Méndez; Ali Ateia Elmabsout; Helena Sävenstrand; Mohamed Khalid Alhaj Awadalla; Åke Strid; Allan Sirsjö; Leif A Eriksson
Journal:  J Chem Inf Model       Date:  2012-09-25       Impact factor: 4.956

View more
  8 in total

Review 1.  Biochemical and physiological importance of the CYP26 retinoic acid hydroxylases.

Authors:  Nina Isoherranen; Guo Zhong
Journal:  Pharmacol Ther       Date:  2019-08-13       Impact factor: 12.310

2.  Preclinical assessment of dual CYP26[A1/B1] inhibitor, DX308, as an improved treatment for keratinization disorders.

Authors:  J G S Veit; Y Poumay; D Mendes; J Kreitinger; L Walker; A Paquet; C Menigot; F Zolezzi; A S Paller; P Diaz
Journal:  Skin Health Dis       Date:  2021-03-26

3.  Robust derivation of transplantable dopamine neurons from human pluripotent stem cells by timed retinoic acid delivery.

Authors:  José M Dias; Andrew F Adler; Mariya Kozhevnikova; Zhanna Alekseenko; Josina Anna van Lunteren; Sara Nolbrant; Ashwini Jeggari; Svitlana Vasylovska; Takashi Yoshitake; Jan Kehr; Marie Carlén; Andrey Alexeyenko; Malin Parmar; Johan Ericson
Journal:  Nat Commun       Date:  2022-06-01       Impact factor: 17.694

4.  Comparison of the ligand binding site of CYP2C8 with CYP26A1 and CYP26B1: a structural basis for the identification of new inhibitors of the retinoic acid hydroxylases.

Authors:  Robert S Foti; Philippe Diaz; Dominique Douguet
Journal:  J Enzyme Inhib Med Chem       Date:  2016-07-17       Impact factor: 5.051

5.  CYP26C1 Is a Hydroxylase of Multiple Active Retinoids and Interacts with Cellular Retinoic Acid Binding Proteins.

Authors:  Guo Zhong; David Ortiz; Alex Zelter; Abhinav Nath; Nina Isoherranen
Journal:  Mol Pharmacol       Date:  2018-02-23       Impact factor: 4.436

Review 6.  Characterization of CYP26B1-Selective Inhibitor, DX314, as a Potential Therapeutic for Keratinization Disorders.

Authors:  Joachim G S Veit; Valérie De Glas; Benoît Balau; Haoming Liu; Florence Bourlond; Amy S Paller; Yves Poumay; Philippe Diaz
Journal:  J Invest Dermatol       Date:  2020-06-04       Impact factor: 8.551

7.  Computational model for fetal skeletal defects potentially linked to disruption of retinoic acid signaling.

Authors:  Jocylin D Pierro; Bhavesh K Ahir; Nancy C Baker; Nicole C Kleinstreuer; Menghang Xia; Thomas B Knudsen
Journal:  Front Pharmacol       Date:  2022-09-06       Impact factor: 5.988

Review 8.  An intracrine view of sex steroids, immunity, and metabolic regulation.

Authors:  Katya B Rubinow
Journal:  Mol Metab       Date:  2018-03-08       Impact factor: 7.422

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.